Researchers determine the clinical and demographic risk factors of paradoxical eczema as well as the overall incidence and biologic-class-specific risk factors and incidence of paradoxical eczema in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An oral ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. IL-23 inhibitors were associated with the lowest ...

- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely ...

On the plus side, an IL-33 inhibitor called itepekimab appeared to help patients keep their asthma under control better than placebo, reported Michael Wechsler, MD, of National Jewish Health in Denver ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 100% of patients treated with 150 mg, 300 mg and 600 mg ...

In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation TREMFYA is the first fully human ...

(MENAFN- Market Press Release) September 28, 2025 8:37 am - The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is projected to reach USD 6.52 billion in 2025, growing at an 11% CAGR through 2032.

HORSHAM, Pa., May 30, 2017 /PRNewswire/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has entered into a worldwide exclusive license ...

Background. The interplay between Candida species and pattern recognition receptors, interleukins, kynurenine, and T cells has been studied in murine and ex vivo human studies, but data are lacking ...